We are live on ! Find out more
SWTX

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

92 hedge funds and large institutions have $1.79B invested in SpringWorks Therapeutics in 2020 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 30 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

22% more capital invested

Capital invested by funds: $1.46B → $1.79B (+$325M)

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

18% more funds holding

Funds holding: 7892 (+14)

6.2% more ownership

Funds ownership: 80.93%87.13% (+6.2%)

3% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 30

Holders
92
Holders Change
+14
Holders Change %
+17.95%
% of All Funds
1.85%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.12%
New
18
Increased
29
Reduced
30
Closed
4
Calls
Puts
Net Calls
Net Calls Change

SWTX Hedge Fund Activity: Q3 2020 in Review

92 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2020, worth a combined $1.79B — up 22% from $1.46B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new SWTX positions and 4 closed out — a net gain of 14 holders — while 29 added to existing stakes and 30 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $35.2M. The largest seller was BVF Inc, cutting an estimated $9.92M.

  • 92 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2020, up from 78 in Q2 2020.
  • Funds reported $1.79B of SpringWorks Therapeutics stock for Q3 2020, up 22% quarter-over-quarter.
  • 18 funds opened new SpringWorks Therapeutics positions in Q3 2020 and 4 closed out, a net change of +14 holders.
  • The largest SpringWorks Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $35.2M added.
  • The largest SpringWorks Therapeutics seller in Q3 2020 was BVF Inc, an estimated $9.92M sold.

Based on aggregated 13F filings for Q3 2020.